Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TKT Replagal Surrogate Data Should Be Reworked For Accelerated Approval

Executive Summary

Transkaryotic Therapeutics' Replagal histologic data should be reevaluated to determine whether they may satisfy a surrogate endpoint for accelerated approval in Fabry Disease, members of FDA's Endocrinologic & Metabolic Drugs Advisory Committee said Jan. 14

You may also be interested in...



Replagal Advisory Committee Will Include Closed Door Session On Manufacturing

FDA’s Cardiovascular and Renal Drugs Advisory Committee will assess Shire biologics’ BLA for the Fabry disease therapy, which already is available in the U.S. due to shortages of competitor Fabrazyme, during a March 27 meeting.

TKT Hopes To Break Even In 2006 Following Hunter Syndrome Therapy BLA

Transkaryotic Therapies expects its Phase III Hunter syndrome therapy to help the company "break even" by late 2006

TKT Hopes To Break Even In 2006 Following Hunter Syndrome Therapy BLA

Transkaryotic Therapies expects its Phase III Hunter syndrome therapy to help the company "break even" by late 2006

Related Content

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel